Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance

Maiko Takahashi, Tetsu Hayashida, Hiroshi Okazaki, Kazuhiro Miyao, Hiromitsu Jinno, Yuukou Kitagawa

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

B-cell translocation gene 2 (BTG2), a gene suppressed in a subset of aggressive breast cancer, is repressed by estrogen. BTG2 inhibits the expression of HER ligands and promotes AKT activation, which plays an essential role in the tamoxifen resistance of estrogen receptor (ER)-positive breast cancer. To determine if BTG2 expression modifies tamoxifen efficacy, a cohort of 60 patients treated with adjuvant tamoxifen monotherapy was analyzed. We found that increased BTG2 expression showed better clinical survival and was the only independent prognostic factor for disease-free survival (hazard ratio, 0.691; 95% confidence interval, 0.495-0.963; P = 0.029). Tamoxifen suppressed the human epidermal growth factor receptor 2 (HER2)-Akt signaling in BTG2 expressing ER-positive breast cancer cells with a correlated increase in sensitivity, whereas BTG2 knockdown abrogated this sensitivity. Consistent with this observation, tamoxifen significantly suppressed the growth ratio, tumor weight and Ki-67 expression in BTG2 expressing breast cancer xenografts in mice. These studies demonstrate that BTG2 is a significant factor in tamoxifen response, acting through modification of AKT activation in ER-positive/HER2-negative breast cancer. Tamoxifen treatment effectively inhibits tumor progression with BTG2 expression in mouse xenograft experiment.

Original languageEnglish
Pages (from-to)675-682
Number of pages8
JournalCancer Science
Volume105
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Tamoxifen
Estrogen Receptors
B-Lymphocytes
Breast Neoplasms
Gene Expression
Genes
Heterografts
Gene Knockdown Techniques
Tumor Burden
Disease-Free Survival
Estrogens
Confidence Intervals
Ligands
Survival
Growth

Keywords

  • Breast cancer
  • BTG2
  • Drug sensitivity
  • Endocrine therapy
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance. / Takahashi, Maiko; Hayashida, Tetsu; Okazaki, Hiroshi; Miyao, Kazuhiro; Jinno, Hiromitsu; Kitagawa, Yuukou.

In: Cancer Science, Vol. 105, No. 6, 2014, p. 675-682.

Research output: Contribution to journalArticle

@article{0ff80ceb38954c0db4365a6f0465e7d4,
title = "Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance",
abstract = "B-cell translocation gene 2 (BTG2), a gene suppressed in a subset of aggressive breast cancer, is repressed by estrogen. BTG2 inhibits the expression of HER ligands and promotes AKT activation, which plays an essential role in the tamoxifen resistance of estrogen receptor (ER)-positive breast cancer. To determine if BTG2 expression modifies tamoxifen efficacy, a cohort of 60 patients treated with adjuvant tamoxifen monotherapy was analyzed. We found that increased BTG2 expression showed better clinical survival and was the only independent prognostic factor for disease-free survival (hazard ratio, 0.691; 95{\%} confidence interval, 0.495-0.963; P = 0.029). Tamoxifen suppressed the human epidermal growth factor receptor 2 (HER2)-Akt signaling in BTG2 expressing ER-positive breast cancer cells with a correlated increase in sensitivity, whereas BTG2 knockdown abrogated this sensitivity. Consistent with this observation, tamoxifen significantly suppressed the growth ratio, tumor weight and Ki-67 expression in BTG2 expressing breast cancer xenografts in mice. These studies demonstrate that BTG2 is a significant factor in tamoxifen response, acting through modification of AKT activation in ER-positive/HER2-negative breast cancer. Tamoxifen treatment effectively inhibits tumor progression with BTG2 expression in mouse xenograft experiment.",
keywords = "Breast cancer, BTG2, Drug sensitivity, Endocrine therapy, Tamoxifen",
author = "Maiko Takahashi and Tetsu Hayashida and Hiroshi Okazaki and Kazuhiro Miyao and Hiromitsu Jinno and Yuukou Kitagawa",
year = "2014",
doi = "10.1111/cas.12410",
language = "English",
volume = "105",
pages = "675--682",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance

AU - Takahashi, Maiko

AU - Hayashida, Tetsu

AU - Okazaki, Hiroshi

AU - Miyao, Kazuhiro

AU - Jinno, Hiromitsu

AU - Kitagawa, Yuukou

PY - 2014

Y1 - 2014

N2 - B-cell translocation gene 2 (BTG2), a gene suppressed in a subset of aggressive breast cancer, is repressed by estrogen. BTG2 inhibits the expression of HER ligands and promotes AKT activation, which plays an essential role in the tamoxifen resistance of estrogen receptor (ER)-positive breast cancer. To determine if BTG2 expression modifies tamoxifen efficacy, a cohort of 60 patients treated with adjuvant tamoxifen monotherapy was analyzed. We found that increased BTG2 expression showed better clinical survival and was the only independent prognostic factor for disease-free survival (hazard ratio, 0.691; 95% confidence interval, 0.495-0.963; P = 0.029). Tamoxifen suppressed the human epidermal growth factor receptor 2 (HER2)-Akt signaling in BTG2 expressing ER-positive breast cancer cells with a correlated increase in sensitivity, whereas BTG2 knockdown abrogated this sensitivity. Consistent with this observation, tamoxifen significantly suppressed the growth ratio, tumor weight and Ki-67 expression in BTG2 expressing breast cancer xenografts in mice. These studies demonstrate that BTG2 is a significant factor in tamoxifen response, acting through modification of AKT activation in ER-positive/HER2-negative breast cancer. Tamoxifen treatment effectively inhibits tumor progression with BTG2 expression in mouse xenograft experiment.

AB - B-cell translocation gene 2 (BTG2), a gene suppressed in a subset of aggressive breast cancer, is repressed by estrogen. BTG2 inhibits the expression of HER ligands and promotes AKT activation, which plays an essential role in the tamoxifen resistance of estrogen receptor (ER)-positive breast cancer. To determine if BTG2 expression modifies tamoxifen efficacy, a cohort of 60 patients treated with adjuvant tamoxifen monotherapy was analyzed. We found that increased BTG2 expression showed better clinical survival and was the only independent prognostic factor for disease-free survival (hazard ratio, 0.691; 95% confidence interval, 0.495-0.963; P = 0.029). Tamoxifen suppressed the human epidermal growth factor receptor 2 (HER2)-Akt signaling in BTG2 expressing ER-positive breast cancer cells with a correlated increase in sensitivity, whereas BTG2 knockdown abrogated this sensitivity. Consistent with this observation, tamoxifen significantly suppressed the growth ratio, tumor weight and Ki-67 expression in BTG2 expressing breast cancer xenografts in mice. These studies demonstrate that BTG2 is a significant factor in tamoxifen response, acting through modification of AKT activation in ER-positive/HER2-negative breast cancer. Tamoxifen treatment effectively inhibits tumor progression with BTG2 expression in mouse xenograft experiment.

KW - Breast cancer

KW - BTG2

KW - Drug sensitivity

KW - Endocrine therapy

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=84901789282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901789282&partnerID=8YFLogxK

U2 - 10.1111/cas.12410

DO - 10.1111/cas.12410

M3 - Article

C2 - 24698107

AN - SCOPUS:84901789282

VL - 105

SP - 675

EP - 682

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 6

ER -